Anne Hatch, DO
Neurology · Phoenix, AZNPI 1457766792
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 69.6% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $7,320 and has fallen 94.6% since, to $392 in 2025.
Across 64 payments — averaging $214.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$10K
- Ipsen Pharma SAS$1K
- Grifols USA, LLC$815
- AbbVie$375
- Argenx US, Inc.$334
- UCB, Inc.$255
- plus $1K from 12 others
Across 94 payments — averaging $4046.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$237K
- Ipsen Pharma SAS$113K
- Adamas Pharmaceuticals, Inc.$30K
What the payments were for
- Consulting fees$6205%
- Speaking & faculty fees$7,22853%
- Travel & lodging$2,01315%
- Food & beverage$3,75827%
- Education$841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $9,535 |
| Ipsen Pharma SAS | 2 | $1,229 |
| Grifols USA, LLC | 3 | $815 |
| AbbVie | 11 | $375 |
| Argenx US, Inc. | 4 | $334 |
| UCB, Inc. | 2 | $255 |
| Johnson & Johnson | 2 | $214 |
| Tanabe Pharma America, Inc. | 4 | $204 |
| Grifols Shared Services North America, Inc. | 1 | $129 |
| EMD Serono, Inc. | 1 | $125 |
| Alnylam Pharmaceuticals Inc. | 1 | $120 |
| Biogen | 2 | $109 |
| EDW Pharma, Inc. | 1 | $73 |
| Acadia Pharmaceuticals Inc | 1 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Kedrion Biopharma, Inc. | 2 | $40 |
| Acorda Therapeutics, Inc | 1 | $20 |
| Akcea Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,703 in reported general payments places this provider in the 75th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 51 | $652,660 |
| Radicava OrsEdaravone | 35 | $483,778 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 13 | $394,069 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 18 | $78,046 |
| Nurtec OdtRimegepant Sulfate | 35 | $50,385 |
| UbrelvyUbrogepant | 20 | $34,519 |
| Aimovig AutoinjectorErenumab-Aooe | 25 | $21,481 |
| Emgality PenGalcanezumab-Gnlm | 22 | $20,907 |
| Ajovy SyringeFremanezumab-Vfrm | 15 | $13,608 |
| BotoxOnabotulinumtoxina | 11 | $13,354 |
| QuliptaAtogepant | 12 | $12,549 |
| Pyridostigmine Bromide | 71 | $4,268 |
| Pregabalin | 147 | $4,182 |
| Mycophenolate Mofetil | 43 | $4,032 |
| Droxidopa | 13 | $3,896 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $47 | $652,66051 claims |
| Kedrion Biopharma, Inc.Gammaked | $40 | $394,06913 claims |
| AbbVieUbrelvy, Botox, Qulipta | $375 | $60,42143 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 388 neurology providers in Arizona.
Other neurology in Phoenix
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
- Kerry KnievelPhoenix$509K
- Lori TravisPhoenix$406K
- Jeffrey GittPhoenix$275K
- Todd SchwedtPhoenix$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.